ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

ClinicalTrials.gov ID: NCT04379050

Public ClinicalTrials.gov record NCT04379050. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 23, 2026, 5:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Extension of Study M15-741 to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease

Study identification

NCT ID
NCT04379050
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AbbVie
Industry
Enrollment
130 participants

Conditions and interventions

Interventions

  • ABBV-951 Drug

Drug

Eligibility (public fields only)

Age range
30 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 7, 2020
Primary completion
Mar 31, 2026
Completion
Mar 31, 2026
Last update posted
Aug 4, 2025

2020 – 2026

United States locations

U.S. sites
15
U.S. states
12
U.S. cities
15
Facility City State ZIP Site status
University of Alabama at Birmingham - Main /ID# 215597 Birmingham Alabama 35233
Banner Sun Health Research Institute /ID# 215579 Sun City Arizona 85351
University of Colorado Hospital /ID# 215625 Aurora Colorado 80045
Parkinson's Disease and Movement Disorders Center of Boca Raton /ID# 215412 Boca Raton Florida 33486
Indiana Clinical Research Cent /ID# 216490 Indianapolis Indiana 46202
Univ Kansas Med Ctr /ID# 215624 Kansas City Kansas 66160
Washington University-School of Medicine /ID# 215472 St Louis Missouri 63110
Dartmouth-Hitchcock Medical Center /ID# 216834 Lebanon New Hampshire 03756
M3 Wake Research Inc. /ID# 215596 Raleigh North Carolina 27612-8106
Legacy Medical Group - Neurology /ID# 215536 Portland Oregon 97232-2003
Baylor College of Medicine /ID# 215401 Houston Texas 77030
Central Texas Neurology Consul /ID# 217013 Round Rock Texas 78681
Univ Texas HSC San Antonio /ID# 215400 San Antonio Texas 78229-3901
Booth Gardner Parkinson's Care Center /ID# 215535 Kirkland Washington 98034-3029
Inland Northwest Research /ID# 215533 Spokane Washington 99202-1342

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04379050, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 4, 2025 · Synced Apr 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04379050 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →